Welcome to our dedicated page for Quantum-Si news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si stock.
Quantum-Si Incorporated develops proteomics technology for single-molecule protein sequencing and protein analysis. Its updates center on benchtop platform development, real-time kinetic-based detection, and product work around Proteus instruments, the KinetIQ Array and Platinum Pro customer use.
Recurring company news includes quarterly financial results and non-GAAP operating measures, Proteus prototype and integrated-instrument sequencing milestones, amino-acid detection coverage, customer sample testing, scientific posters and manuscripts using Quantum-Si technology, investor conference participation, and equity-inducement grants under Nasdaq rules.
Quantum-Si (Nasdaq: QSI) announces an upcoming Nature webinar featuring Dr. Gloria Sheynkman from the University of Virginia on May 15, 2025. The presentation, titled "Precision Proteomics: Next-Gen Protein Sequencing for Proteoform Detection and Characterization," will showcase research utilizing QSI's Platinum® Next-Gen Protein Sequencing™ (NGPS™) platform.
Dr. Sheynkman will present findings from her team's study on tropomyosin proteoforms, demonstrating the platform's capability to detect protein variations at the single-molecule level. The webinar, scheduled for 8:00 a.m. PDT / 11:00 a.m. EDT, highlights QSI's innovative technology that enables single-amino acid resolution and high-specificity detection of endogenous proteins.
Quantum-Si (Nasdaq: QSI), The Protein Sequencing Company, has scheduled its first quarter 2025 financial results announcement for Thursday, May 15, 2025. The company will host a conference call and webcast at 4:30 PM ET on the same day, featuring President and CEO Jeff Hawkins and CFO Jeff Keyes, who will discuss the financial performance and provide a business update.
Interested participants can join via live webcast through the Investors section of Quantum-Si's website under Events and Presentations, or register for a personalized dial-in number to join the call. A replay of the webcast will be available after the event.
Quantum-Si (Nasdaq: QSI) has begun shipping its latest benchtop protein sequencer, Platinum® Pro, designed to make Next-Gen Protein Sequencing™ more accessible globally. The new system builds upon the original Platinum model with enhanced features including:
- An enlarged touchscreen with intuitive user interface
- Flexible local or cloud-based data analysis options
- Pro Mode for custom application development through a Technology Access Program
The system offers single-molecule precision protein analysis through an integrated workflow and is now available in over 30 countries through direct and channel partner networks. According to CEO Jeff Hawkins, Platinum Pro aims to advance proteomics research and enable new biomarker discoveries.
Quantum-Si (Nasdaq: QSI), The Protein Sequencing Company™, has announced its participation in an upcoming DNAnexus webinar focused on proteomics in multi-omics research. The virtual event, scheduled for March 25, 2025, at 8 a.m. PT/11 a.m. ET, will explore how integrating proteomics data with other omics datasets drives new discoveries in disease research, including cancer.
Featured speakers include Meredith Carpenter, PhD from Quantum-Si, Cindy Lawley, PhD from Olink, Thermo Fisher Scientific, and Theresa Wohlever from DNAnexus. The webinar will cover:
- The growing impact of proteomics in multi-omics analysis
- Applications for cancer and other disease research
- Technologies and strategies for large-scale discovery and data analysis
- Tools for orthogonal validation of proteins of interest
Quantum-Si (Nasdaq: QSI), The Protein Sequencing Company™, has announced its participation in an upcoming DNAnexus webinar focused on proteomics in multi-omics research. The virtual event, scheduled for March 25, 2025, at 8 a.m. PT/11 a.m. ET, will explore how integrating proteomics data with other omics datasets drives new discoveries in disease research, including cancer.
Key speakers include Meredith Carpenter, PhD from Quantum-Si, Cindy Lawley, PhD from Olink, Thermo Fisher Scientific, and Theresa Wohlever from DNAnexus. The webinar will cover:
- The growing impact of proteomics in multi-omics analysis
- Applications for cancer and other disease research
- Technologies and strategies for large-scale discovery and data analysis
- Tools for orthogonal validation of proteins of interest
Quantum-Si (Nasdaq: QSI) has announced new employee inducement grants approved by its Board's Compensation Committee. The company granted 20,833 restricted stock units (RSUs) to new employees under its 2023 Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vesting schedule includes 25% vesting on March 20, 2026, with the remaining portion vesting in 12 equal quarterly installments thereafter. Vesting is contingent upon continued employment with Quantum-Si. These equity awards are specifically designed for new hires who were not previously employed by the company, serving as an inducement for joining Quantum-Si.
Quantum-Si (QSI) reported strong Q4 and full year 2024 financial results, achieving its first quarterly revenue over $1 million. Q4 revenue reached $1.2 million with a 51% gross margin, while full-year 2024 revenue totaled $3.1 million, representing 183% year-over-year growth.
The company successfully raised over $86 million in capital between Q4 2024 and early 2025, extending its cash runway into H2 2027. Key developments include the launch of Platinum® Pro in January 2025, new v2 Library Preparation Kit, and Barcoding Kit in December 2024. QSI reported a Q4 net loss of $33.1 million and full-year net loss of $101.0 million.
With $209.6 million in cash and investments as of December 31, 2024, QSI expects significant revenue growth in 2025, supported by new commercial partnerships with Avantor and international distributors.